3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Phase 2
1
Status
Completed
2
Active not recruiting
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Breast
5
Thoracic
4
Genitourinary
3
Gastrointestinal
3
Head & Neck
2
Other solid neoplasm
1
Lymphoid
1
Gynecologic
1
Conditions
Urinary Bladder Neoplasms
157
Carcinoma, Transitional Cell
56
Non-Muscle Invasive Bladder Neoplasms
30
Urethral Neoplasms
24
Carcinoma, Renal Cell
23
Neoplasms
19
Kidney Neoplasms
15
Pancreatic Neoplasms
14
Ovarian Neoplasms
14
Neoplasm Metastasis
13
Carcinoma, Non-Small-Cell Lung
13
Prostatic Neoplasms
12
Ureteral Neoplasms
11
Urologic Neoplasms
9
Colorectal Neoplasms
9
Breast Neoplasms
9
Lung Neoplasms
7
Testicular Neoplasms
6
Stomach Neoplasms
6
Melanoma
6
Sarcoma
5
Urothelial Cancer
4
Squamous Cell Carcinoma of Head and Neck
4
Small Cell Lung Carcinoma
4
Osteosarcoma
4
Colonic Neoplasms
4
Urogenital Neoplasms
3
Triple Negative Breast Neoplasms
3
Recurrence
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Interventions
pembrolizumab
26
lenvatinib
7
belzutifan
5
Saline Solution
4
Docetaxel
4
epacadostat
3
enzalutamide
3
enfortumab vedotin
3
Surgical Procedures, Operative
3
Prednisone
3
Gemcitabine
3
Cisplatin
3
Paclitaxel
2
Dexamethasone
2
Calcium Dobesilate
2
vinflunine
1
pazopanib
1
olaparib
1
Sunitinib
1
Prednisolone
1
Oxaliplatin
1
Fluorouracil
1
Cystectomy
1
Carboplatin
1
Capecitabine
1
CB-1158
1
Bevacizumab
1
Axitinib
1
Albumin-Bound Paclitaxel
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body
×
Gemcitabine
×
Genitourinary
×
Clear all
NCT04700124
2026-02-05
KEYNOTE-B15
Merck Sharp & Dohme LLC
Phase 3
Completed
808 enrolled
NCT03924856
2025-08-28
KEYNOTE-866
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
907 enrolled
NCT05007106
2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2
Completed
613 enrolled